» Articles » PMID: 16690429

Resin 90Y-microsphere Brachytherapy for Unresectable Colorectal Liver Metastases: Modern USA Experience

Overview
Specialties Oncology
Radiology
Date 2006 May 13
PMID 16690429
Citations 102
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Salvage therapy for patients with unresectable colorectal liver metastases that were refractory to oxaliplatin and irinotecan was performed via radioactive microspheres. High doses of radiation were delivered to tumors from permanently implanted 90Y microspheres, delivered through the hepatic arterial vessels.

Methods And Materials: Patients from 7 institutions were selected for treatment after screening-defined vascular access to all the tumors, and imaging-confirmed microspheres would be implanted only in the liver tumors. All patients were followed with laboratory and imaging studies at regular intervals until death. Toxicities, both acute and late, were recorded, and actuarial survival determined.

Results: A total of 208 patients were treated from April 2002 to April 2005. Median follow-up of the 129 men and 79 women is 13 months (range, 1-42 months). Median survival is 10.5 months for responders but only 4.5 months in nonresponders. No treatment-related procedure deaths or radiation-related venoocclusive liver failures were found. Computed tomography partial response was 35%; positron emission tomography response of 91% and reduction in carcinoembryonic antigen of 70% were achieved.

Conclusions: In this group of heavily pretreated patients, radioactive microspheres produced an encouraging median survival, with acceptable toxicity, and a significant objective response rate, which suggests that further investigation of this approach is warranted.

Citing Articles

Locoregional Therapies for Primary and Secondary Hepatic Malignancies.

Serhal M, Riaz A, Salem R, Lewandowski R Cancer Treat Res. 2024; 192:207-232.

PMID: 39212923 DOI: 10.1007/978-3-031-61238-1_11.


The Impact of Local Control on Overall Survival after Y-90 Selective Internal Radiotherapy of Liver Metastases in Oligometastatic Cancer: A Retrospective Analysis.

Yeakel J, Seyedin S, Harada G, Hagopian G, Mahmood S, Bennett R Cancers (Basel). 2024; 16(13).

PMID: 39001464 PMC: 11240767. DOI: 10.3390/cancers16132401.


MIDOS: a novel stochastic model towards a treatment planning system for microsphere dosimetry in liver tumors.

Huesa-Berral C, Withrow J, Dawson R, Beekman C, Bolch W, Paganetti H Eur J Nucl Med Mol Imaging. 2023; 51(6):1506-1515.

PMID: 38155237 PMC: 11043005. DOI: 10.1007/s00259-023-06567-9.


Predictive Value of [Tc]-MAA-Based Dosimetry in Hepatocellular Carcinoma Patients Treated with [Y]-TARE: A Single-Center Experience.

Doppler M, Reincke M, Bettinger D, Vogt K, Weiss J, Schultheiss M Diagnostics (Basel). 2023; 13(14).

PMID: 37510175 PMC: 10378141. DOI: 10.3390/diagnostics13142432.


Interventional radiological therapies in colorectal hepatic metastases.

Vulasala S, Sutphin P, Kethu S, Onteddu N, Kalva S Front Oncol. 2023; 13:963966.

PMID: 37324012 PMC: 10266282. DOI: 10.3389/fonc.2023.963966.